Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128272 | 0.92 | GPR119 (0.39) | CSF1RGPR119FAAHACHE | |
| SCHEMBL4133416 | 0.92 | CSF1R (0.43) | CSF1RGPR119FAAHACHEALOX5AP | |
| SCHEMBL13596405 | 0.91 | GPR119 (0.43) | CSF1RGPR119FAAHACHE | |
| SCHEMBL4129349 | 0.90 | GPR119 (0.41) | GPR119FAAHACHE | |
| SCHEMBL4127421 | 0.90 | ACHE (0.42) | CSF1RACHE | |
| SCHEMBL13597461 | 0.90 | GPR119 (0.40) | CSF1RGPR119FAAHACHE | |
| SCHEMBL4125643 | 0.89 | CSF1R (0.40) | CSF1RGPR119SLC2A1ACHE | |
| SCHEMBL4125644 | 0.89 | CSF1R (0.40) | CSF1RGPR119SLC2A1ACHE | |
| SCHEMBL4119917 | 0.89 | ACHE (0.45) | CSF1RGPR119ACHE | |
| SCHEMBL4134241 | 0.88 | GPR119 (0.39) | CSF1RGPR119FAAHACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | CSF1R 628/4885GPR119 122/4885FAAH 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.